1. Home /
  2. Health Care Equipment & Services

Health Care Equipment & Services

How Crunch Plans to Make Serious Gains After Being Acquired by TPG Growth

How Crunch Plans to Make Serious Gains After Being Acquired by TPG Growth

Crunch announced Monday morning that it was being acquired by TPG Growth. But why was now the right time to sell? Here's what Jim Rowley, CEO of Crunch has to say.

Walgreens Needs More Bottoming Price Action to Get My Recommendation

Walgreens Needs More Bottoming Price Action to Get My Recommendation

Let's stand back a little and get some perspective on how prices have behaved.

5 Blockbuster M&A Deals of 2019

5 Blockbuster M&A Deals of 2019

AbbVie takes over Allergan. But, it's not the biggest deal of 2019...

Another Day, Another Deal: What to Watch from AbbVie, Allergan, Micron, Buffett

Another Day, Another Deal: What to Watch from AbbVie, Allergan, Micron, Buffett

Wall Street woke up to another major deal. Here's what to watch from AbbVie's acquistion of Allergan, Warren Buffett's Kraft comments and Micron earnings after the bell.

Not High on Canopy Growth's Earnings? Take a Deeper Look

Not High on Canopy Growth's Earnings? Take a Deeper Look

At first glance, CGC's report looks like a drag, but you must dig into the weeds to see how timing and the industry are at play.

Long the Apple of My Eye

Long the Apple of My Eye

Going long on the tech giant is more about health care and credit card offerings than the iPhone.

Danaher Could Dip Near-Term, Providing a Buying Opportunity

Danaher Could Dip Near-Term, Providing a Buying Opportunity

DHR shares are up 35% in 2019.

Dexcom Looks Like It Can Finally Break Out on the Topside

Dexcom Looks Like It Can Finally Break Out on the Topside

Let's check the charts and indicators on the glucose-monitoring company.

Medtronic Is Edging Closer to an Upside Breakout on the Charts

Medtronic Is Edging Closer to an Upside Breakout on the Charts

No one knows their business as well as the CEO.

Nektar Therapeutics Jumps on Positive Results From Melanoma Treatment Study

Nektar Therapeutics Jumps on Positive Results From Melanoma Treatment Study

The company says the test revealed patients were experiencing 'deepening and durability of response over time' with the treatment.